Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies
Christoph J. Auernhammer, Christine Spitzweg, Martin K. Angele, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 6, Iss. 5, pp. 404-415
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Neuroendocrine Neoplasms of the Small Bowel and Pancreas
Ashley Kieran Clift, Mark Kidd, Lisa Bodei, et al.
Neuroendocrinology (2019) Vol. 110, Iss. 6, pp. 444-476
Open Access | Times Cited: 102
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos López, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 20, pp. 2304-2312
Open Access | Times Cited: 78
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia
Florian Bösch, Katharina Brüwer, A. Altendorf-Hofmann, et al.
Endocrine Related Cancer (2019) Vol. 26, Iss. 3, pp. 293-301
Open Access | Times Cited: 72
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
Aura D. Herrera‐Martínez, Johannes Hofland, Leo J. Hofland, et al.
Drugs (2018) Vol. 79, Iss. 1, pp. 21-42
Open Access | Times Cited: 65
Macrophage Extracellular Traps: Current Opinions and the State of Research regarding Various Diseases
Weizhen Weng, Zuoyu Hu, Yunfeng Pan
Journal of Immunology Research (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 30
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics
Viviana Benfante, Alessandro Stefano, Muhammad Ali, et al.
Diagnostics (2023) Vol. 13, Iss. 7, pp. 1210-1210
Open Access | Times Cited: 20
The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high‐grade transformation
Samuel Backman, Johan Botling, Helena Nord, et al.
The Journal of Pathology (2024) Vol. 264, Iss. 4, pp. 357-370
Open Access | Times Cited: 6
High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors
Johan Botling, Ángela Lamarca, D. Bajic, et al.
Neuroendocrinology (2019) Vol. 110, Iss. 11-12, pp. 891-898
Closed Access | Times Cited: 48
Insulinoma‐associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts
Iván González, Hsiang‐Chih Lu, Jared A. Sninsky, et al.
Histopathology (2019) Vol. 75, Iss. 4, pp. 568-577
Closed Access | Times Cited: 43
Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors
Sergio Pedraza‐Arévalo, Manuel D. Gahete, Emilia Alors‐Pérez, et al.
Reviews in Endocrine and Metabolic Disorders (2018) Vol. 19, Iss. 2, pp. 179-192
Closed Access | Times Cited: 41
Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro
Xi‐Feng Jin, Christoph J. Auernhammer, Harun Ilhan, et al.
Journal of Nuclear Medicine (2019) Vol. 60, Iss. 9, pp. 1240-1246
Open Access | Times Cited: 40
The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist’s challenge
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, et al.
Radiology and Oncology (2019) Vol. 53, Iss. 4, pp. 373-387
Open Access | Times Cited: 40
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study
Ángela Lamarca, Joakim Crona, Maxime Ronot, et al.
The Oncologist (2019) Vol. 24, Iss. 11, pp. e1082-e1090
Open Access | Times Cited: 38
Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors In Vitro: Antitumoral Effects
Xi‐Feng Jin, Gerald Spöttl, Julian Maurer, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 345-345
Open Access | Times Cited: 34
ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner
Jinhao Chen, Mujie Ye, Jian’an Bai, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 12
Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Management of Small Bowel Neuroendocrine Tumors
Vincent Larouche, Amit Akirov, Sameerah Alshehri, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1395-1395
Open Access | Times Cited: 32
Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts
Xingyu Liu, Danni Li, Tianbao Ma, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
Xi‐Feng Jin, Matilde Pia Spampatti, Christine Spitzweg, et al.
Reviews in Endocrine and Metabolic Disorders (2018) Vol. 19, Iss. 2, pp. 145-158
Closed Access | Times Cited: 30
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Ángela Lamarca, Maxime Ronot, Salma Moalla, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 22, pp. 6692-6699
Open Access | Times Cited: 26
Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors
Shuaishuai Xu, Hao Li, Tianjiao Li, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 22
The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours
Daniel J. Cuthbertson, Jorge Barriuso, Ángela Lamarca, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 22
Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis
Dilmurodjon Eshmuminov, Debora J. Studer, Víctor López López, et al.
Annals of Surgery (2022) Vol. 277, Iss. 5, pp. e1063-e1071
Open Access | Times Cited: 15
EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms
Zhiwen Xiao, Huaxiang Xu, Jonathan Strosberg, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 1, pp. 164-172
Closed Access | Times Cited: 8
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance
Elke Tatjana Aristizabal Prada, Gerald Spöttl, Julian Maurer, et al.
Endocrine Related Cancer (2018) Vol. 25, Iss. 10, pp. 893-908
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top